Epoetin delta is effective for the management of anaemia associated with chronic kidney disease

Curr Med Res Opin. 2006 Dec;22(12):2507-13. doi: 10.1185/030079906X158048.


Objective: To demonstrate the efficacy and safety of epoetin delta for the treatment of anaemia in dialysis patients with chronic kidney disease (CKD).

Research design and methods: This was a 12-week, randomized, double-blind, active-comparator study. CKD patients who were naïve to epoetin treatment and had haemoglobin < 10 g/dL were randomized to epoetin delta 15, 50, 150, or 300 IU/kg or epoetin alfa 50 IU/kg. Patients initially entered a correction phase until they recorded haemoglobin of > or = 11.5 g/dL for two consecutive weekly measurements or one haemoglobin measurement of > or = 13 g/dL (correction success). A maintenance phase followed where the dose was adjusted to maintain haemoglobin > or = 10.5 g/dL. Maintenance success was defined as haemoglobin > 10.5 g/dL at Week 12. Total success was defined as achieving maintenance and correction success.

Main outcome measures: The primary objective was to demonstrate that the proportion of patients achieving total success was greater in the pooled 150 IU/kg and 300 IU/kg groups compared with the 15 IU/kg dose group.

Results: Total success was achieved in 55.6% of patients in the pooled highest epoetin delta group compared with 4.5% in the lowest dose group. There was no significant difference in total success for the epoetin delta and epoetin alfa 50 IU/kg groups. Significant increases in haemoglobin and haematocrit levels were observed in the 150 and 300 IU/kg dose groups. Adverse events occurred at frequencies expected for this patient group.

Conclusions: Epoetin delta was effective in increasing haemoglobin levels in patients with baseline haemoglobin of < 10 g/dL.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anemia / blood
  • Anemia / drug therapy*
  • Anemia / etiology*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Epoetin Alfa
  • Erythropoietin / adverse effects
  • Erythropoietin / pharmacology
  • Erythropoietin / therapeutic use*
  • Female
  • Hematinics / therapeutic use*
  • Hematocrit
  • Hemoglobins / metabolism
  • Humans
  • Kidney Failure, Chronic / complications*
  • Male
  • Middle Aged
  • Recombinant Proteins
  • Treatment Outcome


  • Hematinics
  • Hemoglobins
  • Recombinant Proteins
  • Erythropoietin
  • epoetin delta
  • Epoetin Alfa